Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, Kaplan LM, Fujioka K, Matejkova E, Svacina S, Luzi L, Gnessi L, Navas-Carretero S, Alfredo Martinez J, Still CD, Sannino A, Saponaro C, Demitri C, Urban LE, Leider H, Chiquette E, Ron ES, Zohar Y, Heshmati HM. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity (Silver Spring). 2019 Feb;27(2):205-216.: Obesity (Silver Spring). 2019 Apr;27(4):679
Rodriguez Martinez R, Chang A. Triple Thyroid Carcinoma: What are the clinical
implications? Poster #703. ENDO Society Annual Meeting 2018.
Clarine L, Chang A, Alegre-Border E, Fortmann A, Philis-Tsimikas A, Morrisey R, Clark T.
Comparison of Maternal and Neonatal Outcomes Using Different Glycemic Targets during
Pregnancy. Poster #1475. ADA 77th Scientific Sessions 2017.
Clarine L, Rodriguez Martinez R, Levine M, McGarvey M, Chang A. 22 Month Review of
Immune Checkpoint Inhibitor Associated Endocrine Disorders at a Southern California
Teaching Hospital. Abstract #716. AACE Annual Meeting 2017. PMID 28535141.
Kahan S, Fujioka K. Obesity Pharmacotherapy in Patients With Type 2 Diabetes. Diabetes Spectr. 2017 Nov;30(4):250-257. doi: 10.2337/ds17-0044
Huribal HM, Clarine LH, Levine M. Five Year Experience with Afirma Gene Expression Classifier (GEC) at a Southern California Teaching Hospital. Poster #238. ATA Annual Meeting 2016. Trainee Poster Finalist & Winner.
Levine M. “Empagliflozin Phase 3 Data Overview.” Current Diabetes Reviews 2016; volume 12, issue 4. PubMed#27296042
Fujioka K, O’Neil PM, Davies M, Greenway F, C W Lau D, Claudius B, Skjøth TV, Bjørn Jensen C, P H Wilding J Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016
Clarine L, Chang A. Too Much of a Good Thing – A Rare Case of Licorice Toxicity Caused
by Common Herbal Tea. Abstract #107. AACE Annual Meeting 2016.
Safety and tolerability of medications approved for chronic weight management. Fujioka K. Obesity (Silver Spring). 2015 Apr;23 Suppl 1:S7-11. doi: 10.1002/oby.21094
Current and emerging medications for overweight or obesity in people with comorbidities. Fujioka K. Diabetes Obes Metab. 2015 Jun 4. doi: 10.1111/dom.12502. [Epub ahead of print]
Xavier Pi-Sunyer, M.D., Arne Astrup, M.D., D.M.Sc., Ken Fujioka, M.D et. al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med 2015;373:11-22.
DOI: 10.1056/NEJMoa1411892
Lee MW, Fujioka K. Dietary prescriptions for the overweight patient: the potential benefits of low-carbohydrate diets in insulin resistance. Diabetes Obes Metab. 2011 Mar;13(3):204-6. doi: 10.1111/j.1463-1326.2010.01328
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2010;376(9741):595-605. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Aug 21;376(9741):594. Lancet. 2010 Oct 23;376(9750):1392
Lee MW, Fujioka K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother. 2009 Aug;10(11):1841-5
Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83
The Effects of Grapefruit on Weight and insulin resistance: Relationship to metabolic syndrome K Fujioka, F Greenway, J Sheard. J of Med Food 2006:9(1):49-54
Erondu N, Gantz I, Musser B, Suryawanishi S, Mallick M Addy C, Cote J, Bray G, Fujioka K, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight or obese adults. Cell Metab. 2006 Oct. 4(4):275-282. PMID 1711500
Glycemic control in patients with type 2 diabetes Mellitus switched from twice-daily immediate-release metformin to a Once-daily Extended-release formulation. K Fujioka, M Pans, S Joyal Clinical Therapeutics. Vol. 25, No.2 pp 515-529: 2003
Bupropion SR significantly enhances weight loss when used with a Moderately-intensity lifestyle intervention. Anderson JW, Greenway F, Fujioka K, Gadde K, McKenny J, O’Neil P. Obesity Research 2002.Vol 10#7:633-41